Connect with us

Technology

5N Plus Reports 2023 Fourth Quarter and Annual Financial Results

Published

on

Record reported Adjusted EBITDA1 of $38.3 million in FY 2023Adjusted gross margin1 of 29.0% for FY 2023Net earnings of $2.3 million in Q4 2023 and $15.4 million in FY 2023Net debt to EBITDA ratio1 of 1.69x as at December 31, 2023

MONTRÉAL, Feb. 27, 2024 /CNW/ – 5N Plus Inc. (TSX: VNP) (“5N+” or “the Company”), a leading global producer of specialty semiconductors and performance materials, today announced its financial results for the fourth quarter of fiscal 2023 (“Q4 2023”) and fiscal year (“FY 2023”) ended December 31, 2023. All amounts in this press release are expressed in U.S. dollars unless otherwise stated.

“For FY 2023, we delivered record reported Adjusted EBITDA and significant margin expansion, while sustaining a strong backlog1. Our performance across these key performance indicators is proof that our strategy – focused on commercial excellence, value-added products and long-term partnerships – is delivering tangible results, while also enabling us to provide increased visibility on our near-term growth path.

“Records are made to be broken and it is our objective to do just that in the coming years. We are confident in our approach and, as reflected in our guidance for 2024 and 2025, we expect to be able to keep levelling up our performance. We will continue to leverage our unique position as a trusted partner for ultra-high purity specialty semiconductors and performance materials, and to capitalize on growing demand in critical end markets like terrestrial renewable energy and space solar power,” said Gervais Jacques, President and CEO of 5N+.

Q4 2023 Highlights

Revenue in Q4 2023 reached $65.1 million, compared to $61.0 million for the same period last year. The 7% increase is primarily attributable to higher demand in the Specialty Semiconductors segment, offset by lower revenue in the Performance Materials segment following the strategic exit from the manufacturing of low-margin extractive and catalytic products in 2022.Net earnings in Q4 2023 were $2.3 million compared to a net loss of $8.1 million in Q4 2022. Net earnings in FY 2023 were $15.4 million compared to a net loss of $23.0 million in FY 2022.Adjusted EBITDA in Q4 2023 was $9.0 million, a 35% increase over the $6.7 million for the same period last year. Adjusted EBITDA was $38.3 million in FY 2023, a 28% increase compared to $30.0 million in FY 2022.Adjusted gross margin in FY 2023 was 29.0%, compared to 23.7% in FY 2022.On December 31, 2023, the backlog represented 292 days of annualized revenue, 8 days higher than the previous quarter and 39 days higher than the same period last year, primarily due to increasing demand in both terrestrial renewable energy and space solar power.Net debt1 was $73.8 million as at December 31, 2023, compared to $78.3 million as at December 31, 2022.

_____________________________

1  These measures are not recognized measures under IFRS and do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. See Non-IFRS Measures for more information.

Outlook

In Specialty Semiconductors, 5N+ continues to benefit from its unique position as the leading global supplier of ultra-high purity semiconductor compounds outside China, with extensive expertise and a favourable global footprint resulting in a reliable supply chain. The Company’s products can be found in a wide range of technologies used in critical applications and everyday products.

Growing demand remains the rule in Specialty Semiconductors end markets, particularly in terrestrial renewable energy and space solar power. This positions 5N+ well to capitalize on future opportunities in these high-growth sectors, as well as other markets, including defense, security and medical imaging, and through its long-term partnerships with key customers.

Management expects growth in the Performance Materials segment to be primarily derived from health and pharmaceutical products, which provide high profitability and predictable cashflows. Additional long-term opportunities are expected to stem from product expansion or development initiatives, including through partnerships.

Furthermore, management continues to seek opportunities to increase operational efficiency, while exploring potential acquisitions and partnerships to enhance its own organic growth and leadership market position.

With the visibility afforded to management as a result of the solid execution of its business strategy over the last few years, its improved product mix and strong backlog, management is committed to sustaining its trajectory with respect to Adjusted EBITDA growth and margin improvements. To that end, management is maintaining its previously disclosed projected Adjusted EBITDA range for FY 2024 to be between $45 million and $50 million and expects Adjusted EBITDA for FY 2025 to be between $50 million and $55 million, supported by organic growth.

To meet these objectives, 5N+ will continue to execute on its value-added focused strategy and commercial excellence program, leveraging its competitive advantages stemming from its unique positioning both from a geographic and expertise standpoint. As a trusted partner in the development and manufacturing of critical specialty semiconductors and performance materials with a customer-centric mentality, the Company will also continue methodically investing in its production capacity to serve high-growth markets and strategic global customers.

Conference Call

5N+ will host a conference call on Wednesday, February 28, 2024, at 8:00 am Eastern Time to discuss fourth quarter and annual results for fiscal 2023. All interested parties are invited to participate in the live broadcast on the Company’s website at www.5nplus.com.

To participate in the conference call:

Toronto area: 416-764-8659Toll‐Free: 1-888-664-6392Enter access code: 94847778

A replay of the conference call will be available two hours after the event and until March 6, 2024. To access the recording, please dial 1-888-390-0541 and enter access code 847778.

About 5N Plus Inc.

5N+ is a leading global producer of specialty semiconductors and performance materials. The Company’s ultra‐pure materials often form the core element of its customers’ products. These customers rely on 5N+’s products to enable performance and sustainability in their own products. 5N+ deploys a range of proprietary and proven technologies to develop and manufacture its products. The Company’s products enable various applications in several key industries, including renewable energy, security, space, pharmaceutical, medical imaging and industrial. Headquartered in Montréal, Quebec, 5N+ operates R&D, manufacturing and commercial centers in strategically located facilities around the world including Europe, North America and Asia.

Forward‐Looking Statements

Certain statements in this press release may be forward‐looking within the meaning of applicable securities laws. Such forward‐looking statements are based on a number of estimates and assumptions that the Company believes are reasonable when made, including that 5N+ will be able to retain and hire key personnel and maintain relationships with customers, suppliers and other business partners, that 5N+ will continue to operate its business in the normal course, that 5N+ will be able to implement its growth strategy, that 5N+ will be able to successfully and timely complete the realization of its backlog, that 5N+ will not suffer any supply chain challenges or any material disruption in the supply of raw materials on competitive terms, that 5N+ will be able to generate new sales, produce, deliver, and sell its expected product volumes at the expected prices and control its costs, as well as other factors believed to be appropriate and reasonable in the circumstances. However, there can be no assurance that such estimates and assumptions will prove to be correct. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict and may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward‐looking statements. A description of the risks affecting the Company’s business and activities appears under the heading “Risk and Uncertainties” of the Company’s 2023 MD&A dated February 27, 2024, available on www.sedarplus.ca.

Forward‐looking statements can generally be identified by the use of terms such as “may”, “should”, “would”, “believe”, “expect”, the negative of these terms, variations of them or any similar terms. No assurance can be given that any events anticipated by the forward‐looking statements in this press release will transpire or occur, or if any of them do so, what benefits that 5N+ will derive therefrom. In particular, no assurance can be given as to the future financial performance of 5N+. The forward‐looking statements contained in this press release is made as of the date hereof and the Company has no obligation to publicly update such forward‐looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws. The reader is warned against placing undue reliance on these forward‐looking statements.

5N PLUS INC.
CONSOLIDATED STATEMENTS OF EARNINGS (LOSS)
Years ended December 31
(in thousands of United States dollars, except per share information)

2023

2022

$

$

Revenue

242,371

264,223

Cost of sales

184,833

215,715

Selling, general and administrative expenses

29,410

28,565

Other expenses (income), net

756

32,997

214,999

277,277

Operating earnings (loss)

27,372

(13,054)

Financial expenses

Interest on long-term debt

8,262

5,466

Imputed interest and other interest expense (income)

572

(274)

Foreign exchange and derivative (gain) loss

(136)

42

8,698

5,234

Earnings (loss) before income taxes

18,674

(18,288)

Income tax expense (recovery)

Current

6,674

6,865

Deferred

(3,399)

(2,154)

3,275

4,711

Net earnings (loss)

15,399

(22,999)

Basic earnings (loss) per share

0.17

(0.26)

Diluted earnings (loss) per share

0.17

(0.26)

Net earnings (loss) are completely attributable to equity holders of 5N Plus Inc.

5N PLUS INC.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(in thousands of United States dollars)

December 31

2023

December 31

2022

$

$

Assets

Current

Cash and cash equivalents

34,706

42,691

Accounts receivable

33,437

32,872

Inventories

105,850

86,254

Income tax receivable

1,672

5,488

Derivative financial assets

591

Other current assets

5,707

19,857

Total current assets

181,963

187,162

Property, plant and equipment

84,600

77,951

Right-of-use assets

29,290

30,082

Intangible assets

29,304

31,563

Goodwill

11,825

11,825

Deferred tax assets

8,261

6,002

Other assets

4,959

3,400

Total non-current assets

168,239

160,823

Total assets

350,202

347,985

Liabilities

Current

Trade and accrued liabilities

37,024

40,200

Income tax payable

4,535

8,780

Current portion of deferred revenue

13,437

11,730

Current portion of lease liabilities

1,811

2,136

Current portion of long-term debt

25,000

Total current liabilities

81,807

62,846

Long-term debt

83,500

121,000

Deferred tax liabilities

5,284

6,959

Employee benefit plan obligations

13,393

11,643

Lease liabilities

28,328

28,266

Deferred revenue

5,629

2,354

Other liabilities

3,669

2,141

Total non-current liabilities

139,803

172,363

Total liabilities

221,610

235,209

Equity

128,592

112,776

Total liabilities and equity

350,202

347,985

Non‐IFRS Measures

EBITDA means net earnings (loss) before interest expenses, income tax (recovery) expense, depreciation and amortization. 5N+ uses EBITDA because it believes it is a meaningful measure of the operating performance of its ongoing business, without the effects of certain expenses. The definition of this non-IFRS measure used by the Company may differ from that used by other companies.

EBITDA is reconciled to the most comparable IFRS measure:

(in thousands of U.S. dollars)

Q4 2023

Q4 2022

FY 2023

FY 2022

$

$

$

$

Net earnings (loss)

2,284

(8,146)

15,399

(22,999)

Interest on long-term debt, imputed interest and other interest expense

2,129

716

8,834

5,192

Income tax (recovery) expense

(734)

(292)

3,275

4,711

Depreciation and amortization

4,057

4,051

16,110

17,732

EBITDA

7,736

(3,671)

43,618

4,636

Adjusted EBITDA means operating earnings (loss) as defined before the effect of impairment of inventories, share-based compensation expense (recovery), litigation and restructuring costs (income), impairment of non-current assets, loss on disposal of property, plant and equipment, loss on divestiture of subsidiary, loss on disposal of assets held for sale, and depreciation and amortization. 5N+ uses Adjusted EBITDA because it believes it is a meaningful measure of the operating performance of its ongoing business without the effects of certain expenses. The definition of this non-IFRS measure used by the Company may differ from that used by other companies.

Adjusted EBITDA margin is defined as Adjusted EBITDA divided by revenues.

Adjusted EBITDA is reconciled to the most comparable IFRS measure:

(in thousands of U.S. dollars)

Q4 2023

Q4 2022

FY 2023

FY 2022

$

$

$

$

Revenues

65,063

61,042

242,371

264,223

Operating expenses

(61,023)

(69,261)

(214,999)

(277,277)

Operating earnings (loss)

4,040

(8,219)

27,372

(13,054)

Share-based compensation expense (recovery)

414

(171)

1,432

999

Litigation and restructuring costs (income)

458

3,210

(8,314)

3,823

Impairment of non-current assets

64

672

12,478

Loss on disposal of property, plant and equipment

1,051

Loss on divestiture of subsidiary

7,834

7,834

Loss on disposal of assets held for sale

216

Depreciation and amortization

4,057

4,051

16,110

17,732

Adjusted EBITDA

9,033

6,705

38,323

30,028

Adjusted gross margin is a measure used to monitor the sales contribution after paying cost of sales, excluding depreciation and inventory impairment charges. 5N+ also expressed this measure in percentage of revenues by dividing the gross margin value by the total revenue.

Adjusted gross margin is reconciled to the most comparable IFRS measure:

(in thousands of U.S. dollars)

Q4 2023

Q4 2022

FY 2023

FY 2022

$

$

$

$

Total revenue

65,063

61,042

242,371

264,223

Cost of sales

(49,677)

(47,909)

(184,833)

(215,715)

Gross margin

15,386

13,133

57,538

48,508

Depreciation included in cost of sales

3,189

3,155

12,656

14,208

Adjusted gross margin

18,575

16,288

70,194

62,716

Adjusted gross margin percentage

28.5 %

26.7 %

29.0 %

23.7 %

Backlog represents the expected orders the Company has received, but has not yet executed, and that are expected to translate into sales within the next twelve months, expressed in dollars and estimated in number of days not to exceed 365 days. Bookings represent orders received during the period considered, expressed in number of days, and calculated by adding revenues to the increase or decrease in backlog for the period considered, divided by annualized year revenues. 5N+ uses backlog to provide an indication of expected future revenues in days, and bookings to determine its ability to sustain and increase its revenues.

Net debt is calculated as total debt less cash and cash equivalents. Any introduced IFRS 16 reporting measures in reference to lease liabilities are excluded from the calculation. 5N+ uses this measure as an indicator of its overall financial position.

The net debt to EBITDA ratio is defined as net debt divided by EBITDA.

Total debt and Net debt are reconciled to the most comparable IFRS measure:

(in thousands of U.S. dollars)

As at December 31, 2023

As at December 31, 2022

$

$

Bank indebtedness

Long-term debt including current portion

108,500

121,000

Lease liabilities including current portion

30,139

30,402

Subtotal Debt

138,639

151,402

Lease liabilities including current portion

(30,139)

(30,402)

Total Debt

108,500

121,000

Cash and cash equivalents

(34,706)

(42,691)

Net Debt

73,794

78,309

SOURCE 5N Plus Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

IQST – iQSTEL and Cycurion Form Exclusive Cybersecurity Partnership to Supercharge Expansion into High-Tech, High-Margin Markets

Published

on

By

NEW YORK, Oct. 10, 2024 /PRNewswire/ — iQSTEL Inc. (OTCQX: IQST), a dynamic leader in telecommunications, fintech, electric vehicle (EV), and AI-driven solutions, is thrilled to announce an exclusive partnership with Cycurion, INC. This strategic collaboration will allow iQSTEL to offer Cycurion’s top-tier cybersecurity products exclusively to the U.S. telecommunications industry, while also expanding into other sectors internationally. Leveraging iQSTEL’s global presence across 17 time zones, from California to Melbourne, and 7 offices worldwide, this partnership is set to unleash a new wave of high-margin, high-tech offerings for telecommunications clients in Europe, Latin America, the Middle East, and the United States, all while delivering cutting-edge cybersecurity solutions to an increasingly challenging market.

A Transformational Move for iQSTEL.

This partnership is a bold leap forward in iQSTEL’s ongoing journey to diversify and expand its portfolio. Over the past few years, iQSTEL has meticulously built a strong business platform, earning the trust of its global customer base. Now, with this deep foundation in place, iQSTEL is perfectly positioned to cross-sell high-margin, high-tech products such as Fintech, EV, and AI-based services. With this partnership, iQSTEL is adding cybersecurity to its offerings, further solidifying its presence in emerging markets.

Leandro Iglesias, CEO of iQSTEL, stated:

“This partnership with Cycurion couldn’t have come at a more pivotal time for iQSTEL. We’ve earned the trust of our clients by building a strong foundation, and now we’re amplifying that strength by offering the high-tech solutions they need, especially in cybersecurity. We’re delivering future-proof, high-margin services that not only meet the demands of today’s digital landscape but also cement our leadership in these rapidly growing sectors. Investors should take note: we’re just getting started.”

The partnership is laser-focused on addressing critical challenges faced by telecom operators, including meeting stringent security compliance requirements, navigating a global shortage of cybersecurity professionals, and mitigating the increasing number of data breaches. By combining iQSTEL’s operational excellence with Cycurion’s advanced cybersecurity expertise, the companies are poised to deliver unparalleled security solutions to telecom customers, turning these challenges into high-margin growth opportunities.

A Next-Generation Cybersecurity Strategy

Cycurion’s portfolio of cybersecurity services, powered by artificial intelligence (AI), includes 24/7 monitoring, advanced threat detection, incident response, vulnerability assessments, and compliance management. The AI-driven platform continuously adapts to emerging threats, enhancing its ability to detect and respond to cyber risks in real time. Trusted by government agencies such as FEMA, TSA, and the US Courts, Cycurion’s proven track record of delivering world-class security services will empower iQSTEL to enhance its product lineup, further increasing customer loyalty and securing long-term revenue growth.

This partnership is expected to drive significant revenue growth for iQSTEL, tapping into the rapidly expanding global cybersecurity market, projected to reach $376 billion by 2029.

Kevin Kelly, CEO of Cycurion, commented:

“Our partnership with iQSTEL opens up tremendous opportunities. We’re bringing our cybersecurity expertise to iQSTEL’s already strong business platform, enabling them to offer next-level protection to telecom clients. This isn’t just about security—it’s about enhancing customer confidence, increasing profitability, and ultimately growing both companies’ market share in the cybersecurity space.”

Key Benefits for iQSTEL Customers and Investors:

24/7/365 Threat and Risk Management: Immediate, real-time protection from the most advanced cybersecurity threats.Revenue-Driving Public Confidence: Enhanced security measures lead to greater trust from customers, preventing breaches that could undermine public and stakeholder confidence.Privacy Protection & Compliance: Strengthening privacy safeguards while ensuring clients meet evolving regulatory standards.Volume Pricing & Financial Advantage: iQSTEL’s purchasing power ensures significantly lower cybersecurity costs for customers, while maintaining a competitive edge.Expanding into High-Growth Sectors: With Cycurion’s services, iQSTEL will continue expanding its reach into high-margin markets such as Fintech, EV, and AI, reinforcing its leadership position.

Empowering the Future with iQSTEL’s Strong Business Platform.

This partnership exemplifies iQSTEL’s long-term strategy: leveraging the strong foundation of its customer relationships to seamlessly introduce high-tech, high-margin products. The trust that iQSTEL’s customers place in its services positions the company to capitalize on massive opportunities in rapidly growing industries like cybersecurity, fintech, electric vehicles, and AI.

Investors are invited to join iQSTEL on this exciting journey. With a projected revenue of $290 million for FY-2024 and plans to continue delivering innovative solutions, iQSTEL’s growth trajectory is stronger than ever. This partnership with Cycurion sets the stage for significant revenue expansion and positions iQSTEL as a major player in the high-margin tech markets of the future.

About Cycurion Inc.

Cycurion, headquartered in McLean, Virginia, is a premier cybersecurity provider specializing in multi-layered defense systems, monitoring, incident response, and compliance management. With a strong leadership team and a growing portfolio of services, Cycurion is dedicated to protecting its clients’ most valuable digital assets across both the public and private sectors.

Cycurion’s leadership team brings a wealth of experience from various sectors, including technology, finance, and cybersecurity:

Emmit McHenry, Chairman: Founder of NetCom Solutions International, which grew to nearly $300 million in revenue within six years, with operations in the U.S., UK, and South Africa. He also founded Network Solutions, which was later sold to SAIC. McHenry is a U.S. Marine Corps service-disabled veteran and has held executive positions at major firms like Allstate Insurance.Kevin Kelly, CEO: Former CEO of Halo Privacy, a cybersecurity company, and Heidrick & Struggles, a leading executive search firm. He also served as CEO and President of North America for APP – Asia Pulp and Paper. Kelly holds an MBA from Duke University’s Fuqua School of Business.Alvin McCoy, CFO: Former Managing Partner of Quantum Capital Partners and President & CEO of The McCoy Group, LLC. McCoy managed over $75 billion in new debt origination at Merrill Lynch and has served on the boards of financial institutions with assets up to $5 billion. He holds an MBA in Finance from Duke University.

Key Facts About Cycurion:

Headquarters: McLean, VirginiaR&D Center: Tel Aviv, IsraelStaff: 80 highly skilled employees, with an impressive list of industry certificationsDoD Cleared Facilities30% of employees hold Top Secret security clearances45 large active contracts2023 Year-End Revenue: $19.6 million

Cycurion Security Platform: Powered by artificial intelligence (AI), Cycurion has developed an enhanced, multi-layered SaaS solution designed to protect clients’ digital assets while minimizing false positives. This AI-driven platform continuously improves its threat detection and incident response capabilities, delivering effective defense in an increasingly complex and evolving cyber landscape.

About iQSTEL (Updated Oct. 2024):

iQSTEL Inc. (OTC-QX: IQST) (www.iQSTEL.com) is a US-based multinational publicly listed company in the final stages of the path to becoming listed on NASDAQ. With FY2023 revenues of $144 million and a forecasted $290 million in revenue, alongside positive operating income of seven digits for FY-2024, iQSTEL is positioning itself for explosive growth. iQSTEL’s mission is to serve basic human needs in today’s modern world by making essential tools accessible, regardless of race, ethnicity, religion, socioeconomic status, or identity. The company recognizes that modern human needs such as physiological, safety, relationship, esteem, and self-actualization are marginalized without access to ubiquitous communications, financial freedom, clean, affordable mobility, and information.

iQSTEL has been building a strong business platform with its customers, and by leveraging this trust, the company is now beginning to sell high-tech, high-margin products across its divisions. iQSTEL is strategically positioned to achieve $1 billion in revenue by 2027 through organic growth, acquisitions, and high-margin product expansion.

Telecommunications Services Division (Communications):
Includes VoIP, SMS, International Fiber-Optic, Proprietary Internet of Things (IoT), and a Proprietary Mobile Portability Blockchain Platform.Fintech Division (Financial Freedom):
Provides remittance services, top-up services, a MasterCard Debit Card, US bank accounts (no SSN required), and a Mobile App.Electric Vehicles (EV) Division (Mobility):
Offers Electric Motorcycles and plans to launch a Mid-Speed Car.Artificial Intelligence (AI) Services Division (Information and Content):
Features an enriched, immersive white-label proprietary AI-Enhanced Metaverse platform that provides access to products, services, entertainment, information, and customer support in a virtual 3D interface.Cybersecurity Services:
Through a new partnership with Cycurion, iQSTEL will offer advanced cybersecurity solutions, including 24/7 monitoring, threat detection, incident response, vulnerability assessments, and compliance management, providing essential protection to telecommunications clients and beyond.

iQSTEL has completed 11 acquisitions since June 2018 and continues to develop an active pipeline of potential future acquisitions, further expanding its suite of products and services both organically and through mergers and acquisitions.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and iQSTEL Inc. undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Company Website
www.iqstel.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/iqst—iqstel-and-cycurion-form-exclusive-cybersecurity-partnership-to-supercharge-expansion-into-high-tech-high-margin-markets-302272356.html

SOURCE iQSTEL

Continue Reading

Technology

CULT Food Science Subsidiary Further Foods Welcomes New Head of Sales and Marketing

Published

on

By

Kevin Ryan joins Noochies! team to drive growth and innovation

TORONTO, Oct. 10, 2024 /PRNewswire/ – CULT Food Science Corp. (“CULT” or the “Company”) (CSE: CULT) (OTC: CULTF) (FRA: LN00), a disruptive food technology platform pioneering the commercialization of lab grown meat and cellular agriculture to reshape the global food industry, is pleased to announce that Kevin Ryan will be joining its subsidiary, Further Foods Inc., as the Head of Sales and Marketing for its innovative pet food brand, Noochies!

Key Takeaways:

Kevin brings a wealth of pet food industry experience to Noochies! Head of Sales and Marketing roleNoochies! brand is poised for retail sales growth both in North America and internationally

In his new role, Kevin will lead the development and implementation of all sales and marketing strategies aimed at achieving revenue targets and expanding distribution. He will guide the growth of the Noochies! brand into new markets and channels, while building and maintaining strong relationships with key clients, distributors and retail partners. Additionally, he’ll spearhead all consumer and digital marketing initiatives, overseeing the development and execution of the brand’s positioning, messaging and campaigns. Working closely with the Company’s CEO, Kevin will also focus on driving growth through direct-to-consumer platforms, including the company’s own website and 3rd party marketplaces like Amazon and Chewy.

No stranger to the pet industry, Kevin previously served as the International Sales Manager for Midwestern Pet Foods, Inc. While there, he managed the brand’s presence, sales channel and profitability outside of the United States through proactive and assertive marketing initiatives. Prior to that, he served as the Global Marketing Director for TOP 1 Oil Products Co. USA, where he expanded the brand’s global presence, sales channels and profitability across 40 international accounts, while also setting five Guinness World Records.

Management Commentary

“We are thrilled to welcome Kevin to the Noochies! team,” commented Mitchell Scott, CEO of CULT Food Science. “His expertise and ability to identify market opportunities, combined with his strategic approach to both sales and marketing, will be instrumental in driving our growth and establishing Noochies! as a top brand in the global specialty pet market.”

About CULT Food Science

CULT Food Science is a disruptive food technology platform pioneering the commercialization of lab grown meat and cellular agriculture to reshape the global food industry. CULT’s robust portfolio of investments in cutting-edge, venture-backed cellular agriculture and lab-grown meat companies provides widespread investor access to the future of food. Backed by a team of experts with extensive experience in food technology and launching consumer food products, CULT is committed to being at the forefront of the food revolution.

About Further Foods

Further Foods is revolutionizing pet nutrition through its innovative brand, Noochies! Noochies! leverages advanced cellular agriculture technologies to create pet food products with superior nutrition profiles and ethical standards. Noochies! recently introduced the world’s first freeze-dried, high-protein, nutrient-rich pet treats made without factory farming. Noochies! products are currently available for sale in the United States and Canada at select retailers and online at https://www.noochies.co/.

Additional information can be found by viewing the Company’s website at cultfoodscience.com or its regulatory filings on sedar.com.

On behalf of the Board of Directors of the Company,

CULT FOOD SCIENCE CORP.

“Mitchell Scott”
Mitchell Scott, Chief Executive Officer

Forward-Looking Information:

Information set forth in this news release may involve forward-looking statements. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address a company’s expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include but are not limited to the following risks: those associated with marketing and sale of securities; the need for additional financing; reliance on key personnel; the potential for conflicts of interest among certain officers or directors with certain other projects; and the volatility of common share price and volume. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and except as required by law, the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements. For further information on risk, investors are advised to see the Company’s MD&A and other disclosure filings with the regulators which are found at sedar.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cult-food-science-subsidiary-further-foods-welcomes-new-head-of-sales-and-marketing-302272590.html

SOURCE Cult Food Science Corp

Continue Reading

Technology

Clario and PathAI Collaborate to Deliver Integrated Solution for GI Clinical Trials

Published

on

By

Partnership combines revolutionary digital pathology and endoscopy solutions, enhancing drug development for IBD and other GI disorders

Strategic Partnership: Streamlined, single-vendor solution improves diagnostic accuracy, boosts efficiency, and enables reliable turnaround times in gastrointestinal (GI) clinical trials.

Advanced GI Solutions: Enhances trial efficiency with AI-powered solutions, including reading for ulcerative colitis (UC) from Clario and histopathology services from PathAI.

Integrated Workflow: Combines endoscopic and histopathology endpoints with simplified processes for CROs, sponsors, and investigational sites.

PHILADELPHIA, Oct. 10, 2024 /PRNewswire/ — Clario, a leading provider of endpoint data solutions to the clinical trials industry, is excited to announce a strategic partnership with PathAI, a leader in AI-powered digital pathology solutions aimed at improving diagnostic accuracy and efficiency. This collaboration offers a single-vendor solution for efficient anatomical pathology services and next-generation video endoscopy analysis.

This co-delivery model streamlines endoscopic and histopathology endpoints to improve efficiency in global GI studies. CROs and sponsors will benefit from an end-to-end process that covers training, logistics, tissue processing, slide digitization, image analysis, and data transfers all with the medical and scientific oversight of our experts. Sites will experience simplified workflows with improved training, reporting, and document management.

“At Clario we have long been at the forefront of supporting GI clinical trials, and we are excited to augment our strengths with PathAI’s capabilities in the area of discovery and patient care,” said Marcela Vieira, M.D., Clario’s Medical Director of Gastroenterology. “The combination of endoscopy and histopathology promises to unlock new avenues for clinical research, and we are proud to be in this leadership position with our partners at PathAI.”

Clario has extensive experience in GI trials, having supported over 130 studies through advanced imaging solutions like endoscopy, MRI, and ultrasound. Their scientists and technologies help reduce site burden and enhance trial efficiency with AI-supported reading for UC and HD-video endoscopy support.

PathAI bolsters the partnership with its expert GI pathologist network and cutting-edge anatomical pathology services while optimizing specimen handling and histological assessments. Their AI-powered tools enhance UC assessment, minimize variability in histological scoring, and expedite biomarker discovery.

“We’re thrilled to partner with Clario to provide a cutting-edge solution for IBD clinical trials,” said Matt Grow, Chief Business Officer & President of Biopharma at PathAI. “Our collaboration will offer an integrated approach in histology and endoscopy for assessing therapeutic efficacy, accelerating biomarker discovery and therapy development in IBD.”

About Clario

Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac solutions, medical imaging, precision motion, and respiratory endpoints.

For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported over 26,000 clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012.

For more information, visit Clario.com or follow on LinkedIn.

About PathAI

Headquartered in Boston, PathAI is the only AI-focused technology company providing comprehensive precision pathology solutions, from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with over 15 million annotations, its AI-powered models optimize pathology sample analysis, improving efficiency and accuracy in interpretation while gauging therapeutic efficacy and accelerating drug development for complex diseases.

For more information, visit pathai.com 

Media Contact:
media@clario.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/clario-and-pathai-collaborate-to-deliver-integrated-solution-for-gi-clinical-trials-302271866.html

SOURCE Clario

Continue Reading

Trending